Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0021 | 0.6188 | 0.6188 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 1 | 1 |
Onchocerca volvulus | 0.0026 | 1 | 0.5 | |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 0.6188 | 0.5 |
Echinococcus multilocularis | lamin | 0.0026 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0026 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0021 | 0.6188 | 0.5 |
Echinococcus granulosus | lamin dm0 | 0.0026 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0026 | 1 | 1 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0021 | 0.6188 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.9646 | 0.9646 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0021 | 0.6188 | 0.5 |
Schistosoma mansoni | lamin | 0.0026 | 1 | 1 |
Schistosoma mansoni | lamin | 0.0026 | 1 | 1 |
Schistosoma mansoni | intermediate filament proteins | 0.0026 | 1 | 1 |
Echinococcus granulosus | lamin | 0.0026 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0026 | 1 | 1 |
Echinococcus granulosus | intermediate filament protein | 0.0026 | 1 | 1 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 0.6188 | 0.5 |
Toxoplasma gondii | exonuclease III APE | 0.0021 | 0.6188 | 0.5 |
Echinococcus multilocularis | musashi | 0.0026 | 1 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0021 | 0.6188 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 0.6188 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0021 | 0.6188 | 0.5 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0021 | 0.6188 | 0.5751 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0021 | 0.6188 | 0.6188 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 0.6188 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0021 | 0.6188 | 0.6188 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0021 | 0.6188 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0021 | 0.6188 | 0.5 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0021 | 0.6188 | 0.5 |
Echinococcus multilocularis | lamin dm0 | 0.0026 | 1 | 1 |
Onchocerca volvulus | 0.0026 | 1 | 0.5 | |
Trichomonas vaginalis | ap endonuclease, putative | 0.0021 | 0.6188 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0021 | 0.6188 | 0.5 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0014 | 0.1026 | 0.1026 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | Antileishmanial activity against Leishmania infantum MHOM/MA/67/ITMAP263 intracellular amastigotes assessed as reduction in parasite growth after 3 days by fluorometrically | ChEMBL. | 20194690 | |
Activity (functional) | Antiparasitic activity against chloroquine-sensitive Plasmodium falciparum Ghana assessed as reduction in parasite growth after 3 days by fluorimetry | ChEMBL. | 20194690 | |
Activity (functional) | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen CL2 s-galactosidase strain assessed as reduction in parasite growth after 3 days by fluorometrically | ChEMBL. | 20194690 | |
IC50 (functional) | > 64 uM | Antitrypanosomal activity against suramin sensitive Trypanosoma brucei brucei Lister 427 assessed as reduction in parasite growth after 3 days by fluorometrically | ChEMBL. | 20194690 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.